|
|
|
|
| LEADER |
01571nam a2200289 u 4500 |
| 001 |
EB001029780 |
| 003 |
EBX01000000000000000823333 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
150411 r ||| eng |
| 245 |
0 |
0 |
|a Tocilizumab (Actemra, intravenous)
|h Elektronische Ressource
|b for the treatment of signs and symptoms of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have responded inadequately to previous therapy with disease-modifying antirheumatic drugs and systemic corticosteroids
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2014, [2014]
|
| 300 |
|
|
|a 1 PDF file (vii, 65 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Antibodies, Monoclonal, Humanized / adverse effects
|
| 653 |
|
|
|a Arthritis, Juvenile / drug therapy
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Antibodies, Monoclonal, Humanized / therapeutic use
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Common drug review
|
| 500 |
|
|
|a Title from PDF caption. - "August 2014."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK253470
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a The objective of this systematic review is to examine the beneficial and harmful effects of IV tocilizumab in the treatment of active polyarticular juvenile idiopathic arthritis (pJIA)
|